Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 5/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7172810 | 0.84 | HIF1A (0.50) | HIF1AKDM4ESMN1; SMN2 | |
| SCHEMBL9262554 | 0.84 | HIF1A (0.50) | HIF1AKDM4ESMN1; SMN2 | |
| SCHEMBL7172808 | 0.84 | HIF1A (0.50) | HIF1AKDM4ESMN1; SMN2 | |
| SCHEMBL11937252 | 0.83 | GFER (0.39) | HIF1AKMT2AMEN1KDM4ESMN1; SMN2 | |
| SCHEMBL9894742 | 0.82 | KMT2A (0.45) | HIF1AKMT2AMEN1 | |
| SCHEMBL8158961 | 0.82 | HIF1A (0.47) | HIF1AKDM4ESMN1; SMN2 | |
| SCHEMBL9894740 | 0.82 | KMT2A (0.45) | HIF1AKMT2AMEN1 | |
| SCHEMBL8158964 | 0.82 | HIF1A (0.47) | HIF1AKDM4ESMN1; SMN2 | |
| SCHEMBL9894739 | 0.82 | KMT2A (0.45) | HIF1AKMT2AMEN1 | |
| SCHEMBL11937249 | 0.81 | CNR1 (0.39) | HIF1AKMT2AMEN1SMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8227456-B2 | Pharmaceutical composition for preventing and treating metabolic bone diseases containing alpha-arylmethoxyacrylate derivatives | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2012-07-24 | — | — | US | disclosed |
| US-8227456-B2 | Pharmaceutical composition for preventing and treating metabolic bone diseases containing alpha-arylmethoxyacrylate derivatives | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2012-07-24 | — | — | US | disclosed |
| US-7879835-B2 | treating osteoporosis, comprising administering drugs such as (E)-methyl 2-(2-((4-octylphenoxy)methyl)-3-methoxyacrylate, which inhibit osteoclast formation or resorption activity; side effect reduction | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2011-02-01 | — | — | US | disclosed |
| US-7879835-B2 | treating osteoporosis, comprising administering drugs such as (E)-methyl 2-(2-((4-octylphenoxy)methyl)-3-methoxyacrylate, which inhibit osteoclast formation or resorption activity; side effect reduction | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2011-02-01 | — | — | US | disclosed |
| US-20100256367-A1 | Pharmaceutical Composition For Preventing and Treating Metabolic Bone Diseases Containing Alpha-Arylmethoxyactylate Derivatives | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2010-10-07 | — | — | US | disclosed |
| US-20100256367-A1 | Pharmaceutical Composition For Preventing and Treating Metabolic Bone Diseases Containing Alpha-Arylmethoxyactylate Derivatives | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2010-10-07 | — | — | US | disclosed |
| US-20080280901-A1 | Pharmaceutical Composition for Preventing and Treating Metabolic Bone Diseases Containing Alpha-Arylmethoxyacrylate Derivatives | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2008-11-13 | — | — | US | disclosed |
| US-20080280901-A1 | Pharmaceutical Composition for Preventing and Treating Metabolic Bone Diseases Containing Alpha-Arylmethoxyacrylate Derivatives | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256367-A1 | Pharmaceutical Composition For Preventing and Treating Metabolic Bone Diseases Containing Alpha-Arylmethoxyactylate Derivatives | ARSA, BMP2, BMP1 | HIF1A 1136/4885KMT2A 2716/4885MEN1 1840/4885 |
| US-20080280901-A1 | Pharmaceutical Composition for Preventing and Treating Metabolic Bone Diseases Containing Alpha-Arylmethoxyacrylate Derivatives | CYP24A1, SOST, ACP3 | HIF1A 836/4885KMT2A 3203/4885MEN1 962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.